Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR – Get Rating)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.86 and traded as low as $4.10. Eiger BioPharmaceuticals shares last traded at $4.11, with a volume of 173,324 shares.
Wall Street Analysts Forecast Growth
EIGR has been the subject of several recent analyst reports. BTIG Research reduced their price objective on shares of Eiger BioPharmaceuticals from $57.00 to $48.00 and set a “buy” rating for the company in a research report on Wednesday, September 7th. StockNews.com cut shares of Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 4th.
Eiger BioPharmaceuticals Stock Down 1.4 %
The business’s fifty day moving average price is $5.63 and its 200 day moving average price is $6.86. The firm has a market capitalization of $181.13 million, a price-to-earnings ratio of -1.71 and a beta of 1.44. The company has a current ratio of 5.45, a quick ratio of 5.34 and a debt-to-equity ratio of 0.50.
Hedge Funds Weigh In On Eiger BioPharmaceuticals
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.
- Get a free copy of the StockNews.com research report on Eiger BioPharmaceuticals (EIGR)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.